← Leaderboards
Suzanne McCluskey
Massachusetts General Hospital
$4,542,101
Attributed
$4,922,952
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,922,952 · 4
By mechanism
R01$3,413,769 · 2
K23$1,027,267 · 1
R21$481,916 · 1
Top collaborators
- Jonathan Li2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Mathias Lichterfeld$34,368,889
- Schahram Akbarian$48,610,378
- David T Scadden$62,181,067
- Richard T D'aquila$62,924,506
- Rafael Meza$13,336,497
Others in their field
Other Emerging Leaders on “Tenofovir”
- Leah Johnson · Research Triangle Institute$10,876,154
- Kenneth Kiggundu Mugwanya · University Of Washington$7,006,296
- Jillian Pintye · University Of Washington$6,586,605
- Benson Edagwa · University Of Nebraska Medical Center$5,899,034
- Matthew A. Spinelli · University Of California, San Francisco$5,446,997
- Giffin Daughtridge · Ursure, Inc.$4,508,676
Research focus
TenofovirDrug ResistanceUgandaAntiretroviral TherapyGuidelinesClinical TrialsParticipantResearch PersonnelResistanceViral Load ResultUnited States National Institutes Of HealthFailureAfrica South Of The SaharaInnovationAdherenceGenotypeFundingRegimenLamivudineReportingUrineCostTreatment FailureInternational
Grant awards (15)
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study)$632,214
R01 · FY2025 · AI · contact PI
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa$278,479
R01 · FY2025 · AI · contact PI
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa$248,084
R01 · FY2025 · AI · contact PI
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa$138,865
R01 · FY2025 · AI · contact PI
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study)$129,488
R01 · FY2025 · AI · contact PI
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa$643,482
R01 · FY2024 · AI · contact PI
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa$648,976
R01 · FY2023 · AI · contact PI
Virologic and pharmacologic determinants of dolutegravir failure in East Africa$196,314
K23 · FY2023 · AI · contact PI
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure for Individuals on TLD in Sub-Saharan Africa$694,181
R01 · FY2022 · AI · contact PI
Virologic and pharmacologic determinants of dolutegravir failure in East Africa$207,359
K23 · FY2022 · AI · contact PI
Virologic and pharmacologic determinants of dolutegravir failure in East Africa$227,333
K23 · FY2021 · AI · contact PI
A urine tenofovir immunoassay to distinguish adherence versus resistance-based HIV treatment failure$211,468
R21 · FY2020 · AI · contact PI
Virologic and pharmacologic determinants of dolutegravir failure in East Africa$197,390
K23 · FY2020 · AI · contact PI
A urine tenofovir immunoassay to distinguish adherence versus resistance-based HIV treatment failure$270,448
R21 · FY2019 · AI · contact PI
Virologic and pharmacologic determinants of dolutegravir failure in East Africa$198,871
K23 · FY2019 · AI · contact PI